The yield of peripheral blood stem cells (PBSC) in hematological or solid tumour patients treated with high dose chemotherapy and hemopoietic growth factors No significant financial relationships to ...
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
Incyte has expanded its graft-versus-host disease (GVHD) offerings beyond Jakafi. The new addition comes from axatilimab, a CSF-1R inhibitor partnered with Syndax Pharmaceuticals. Wednesday, the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback